[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ischemic-strokes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ischemic-strokes":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100646183","phase-4-ciprofol-vs-propofol-for-hemodynamic-stability-in-patients-having-general-anesthesia-for-endovascular-thrombectomy-after-ischemic-stroke-100646183",false,"NCT07696208","Ciprofol vs Propofol for Hemodynamic Stability in Patients Having General Anesthesia for Endovascular Thrombectomy After Ischemic Stroke","Ciprofol vs Propofol for Hemodynamic Stability in Patients Having General Anesthesia for Endovascular Thrombectomy After Ischemic Stroke: A Multicenter Randomized Open-label Parallel-group Trial (CONSTANCY)","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Clinical diagnosis of AIS.\n3. CT\u002FMRI-confirmed absence of intracranial hemorrhage.\n4. Eligible for EVT.\n5. NIHSS score ≥2.\n6. ASA physical status I-III.\n7. Signed informed consent.\n\nExclusion Criteria:\n\n1. Pre-existing severe neurological deficits (mRS 3-5).\n2. Shock.\n3. Severe cardiac disease.\n4. Contraindications to EVT per AHA guidelines.\n5. Participation in conflicting clinical trials.","ALL","18 Years",{"count":19,"type":20},124,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Endovascular therapy (EVT) improves the prognosis of patients with acute ischemic stroke (AIS). EVT has been established as a standard of care for AIS caused with large vessel occlusion based on numerous randomized controlled trials. However, despite extensive attention to post-EVT blood pressure management as a potentially modifiable factor, the ability to achieve high reperfusion rates does not consistently translate into functional independence for a substantial number of patients. Thus, the focus has turned to the intra-procedural period, where blood pressure management may play a critical but underexamined role in determining functional outcomes independent of post-EVT care.\n\nGuideline recommendation to maintain the blood pressure lowered to 185\u002F110 mmHg before the EVT procedure in patients who have not received intravenous thrombolysis therapy. However, studies of blood pressure before reperfusion in this patient group have produced conflicting results. Thus, although randomized trials evaluating pre-thrombectomy blood pressure targets are yet unavailable, accumulating evidence suggests that active blood pressure lowering before reperfusion may be harmful, which underscores the importance of maintaining hemodynamic stability during the EVT procedure.\n\nIn this context, anesthetic management is a key determinant of intraprocedural blood pressure control. Propofol is the most commonly used general anesthetic during EVT surgery. However, propofol is a powerful venodilator and often provokes hypotension which may be especially detrimental in AIS patients. Ciprofol, a novel anesthetic\u002Fsedative, has been proven to possess excellent efficacy and safety which provides definitive general anesthesia\u002Fsedation while minimizing respiratory and hemodynamic depression. Before and during EVT, patients with hemodynamic stability may have better outcomes. Using ciprofol as the anesthesia agent may reduce the incidence and severity of hemodynamic instability during EVT. Therefore, it is of significant research value to investigate whether the use of ciprofol for general anesthesia is beneficial in AIS patients undergoing EVT.",[26,27],"Hemodynamic Stability","Ischemic Strokes",[29,30,26,31,32,33],"Ciprofol","Propofol","General Anesthesia","Endovascular Thrombectomy","Ischemic Stroke","NOT_YET_RECRUITING","2026-07-06",{"date":37,"type":38},"2026-07-10","ACTUAL",{"date":40,"type":20},"2026-07-01",{"date":42,"type":20},"2028-05-31",{"name":44,"class":45},"RenJi Hospital","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100640297","phase-2-spatiotemporal-evolution-of-traditional-chinese-medicine-mechanisms-in-acute-ischemic-stroke-treated-with-dengzhan-xixin-and-dengzhan-shengmai-100640297","NCT07591883","Spatiotemporal Evolution of Traditional Chinese Medicine Mechanisms in Acute Ischemic Stroke Treated With Dengzhan Xixin and Dengzhan Shengmai","STEM-DZ","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Meeting the diagnostic criteria for acute ischemic stroke in accordance with the Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke in China 2023\n3. Within 48 hours after the first onset\n4. National Institutes of Health Stroke Scale (NIHSS) score ranging from 4 to 25 points\n5. Voluntarily signed informed consent.\n\nExclusion Criteria:\n\n1. Pre-stroke modified Rankin Scale (mRS) score ≥ 2\n2. Patients with transient ischemic attack (TIA), complicated with cerebral hemorrhage or subarachnoid hemorrhage\n3. patients with brain tumor, Alzheimer's disease, psychosis, or a confirmed diagnosis of dementia\n4. Patients undergoing endovascular thrombectomy\n5. Patients with severe cardiac diseases such as valvular heart disease, infective endocarditis, myocardial infarction, heart failure, severe hepatic or renal insufficiency, respiratory failure, malignant tumor, or massive gastrointestinal hemorrhage\n6. Patients who have used any preparations containing the same ingredients as the study drug (e.g., Erigeron breviscapus, ginseng, dwarf lilyturf tuber, schisandra chinensis, etc.) within the past 2 weeks\n7. Patients with a history of allergy to the study drug or preparations containing the same ingredients\n8. Pregnant or lactating women\n9. Patients judged by the investigators as unsuitable for participation in this trial.",{"count":55,"type":20},358,[57,58],"PHASE2","PHASE3","To integrate large-scale RCT data on clinical symptoms, TCM syndromes, prognosis, and multi-omics profiles, construct a spatiotemporal dynamic network for disease-syndrome evolution of acute ischemic stroke (AIS) in the acute and recovery phases, evaluate the efficacy and safety of sequential treatment with Erigeron breviscapus-Dengzhan Shengmai for AIS, and provide evidence for precise syndrome differentiation and individualized therapy.Secondary Objective:To investigate the optimal time window and key intervention targets of sequential treatment with Erigeron breviscapus-Dengzhan Shengmai for AIS.",[27,61,62],"Traditional Chinese Medicine (TCM)","Prognosis",[33,61,64,65],"Dianzhizhengmai Capsules","Dengzhanxixin Injection","2026-05-11",{"date":68,"type":38},"2026-05-18",{"date":70,"type":20},"2026-06-01",{"date":72,"type":20},"2029-07-31",{"name":74,"class":45},"Guangdong Provincial Hospital of Traditional Chinese Medicine"]